Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new eye drop tame uveitis inflammation without steroids?

NCT ID NCT07136805

Disease control Sponsor: VivaVision Biotech, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This trial tests an experimental eye drop called VVN461 in people with non-infectious anterior uveitis, a condition causing inflammation inside the front of the eye. Participants receive either VVN461 or a standard steroid eye drop for four weeks. The study measures whether VVN461 can reduce inflammatory cells in the eye as effectively as the steroid, potentially offering a safer alternative.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VVN461 ophthalmic solution (an experimental eye drop)
What this could lead to
If successful, VVN461 could offer a new steroid-sparing option to control eye inflammation in anterior uveitis, potentially reducing steroid-related side effects.
What could go wrong
This is a phase III trial, but success is not guaranteed. The drug may not match the steroid's effectiveness, and eye drops can cause irritation or other local side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

154 people

The number who actually took part.

Started

Nov 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At the time of signing the informed consent form (ICF), the subject must be aged 18 to 70 years (inclusive); * At screening, the affected eye is diagnosed with non-infectious anterior uveitis (acute or recurrent acute, only unilateral eye affected patients are included); * At screening, the ACC grade of the affected eye is 2+ or 3+ \[SUN criteria\]; * At screening, the ACF grade of the affected eye is ≥1 \[SUN criteria\]; Exclusion Criteria: * At screening, the affected eye has an ACC grade of 4+ or hypopyon * Diagnosis of intermediate uveitis, posterior uveitis, or panuveitis in either eye at the time of screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-infectious anterior uveitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-infectious anterior uveitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-infectious anterior uveitis

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.